Published in J Infect Dis on November 15, 2007
Ebola haemorrhagic fever. Lancet (2011) 8.28
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Ebola vaccination: if not now, when? Ann Intern Med (2014) 1.57
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Animal models for Ebola and Marburg virus infections. Front Microbiol (2013) 1.51
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Replication-deficient ebolavirus as a vaccine candidate. J Virol (2009) 1.32
Current ebola vaccines. Expert Opin Biol Ther (2012) 1.30
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science (2015) 1.26
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis (2011) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J (2011) 1.21
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20
Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci U S A (2014) 1.12
Characterization of 47 MHC class I sequences in Filipino cynomolgus macaques. Immunogenetics (2008) 1.10
Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology (2010) 1.09
Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef (2011) 1.09
Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol (2013) 1.08
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology (2008) 1.07
Mouse models for filovirus infections. Viruses (2012) 1.07
Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog (2013) 1.07
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
Ebolavirus vaccines for humans and apes. Curr Opin Virol (2012) 1.01
A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology (2009) 1.01
The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol (2013) 1.00
Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis (2011) 0.99
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis (2013) 0.99
Filovirus vaccines. Hum Vaccin (2011) 0.98
Study of cynomolgus monkey (Macaca fascicularis) DRA polymorphism in four populations. Immunogenetics (2010) 0.97
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Clinical development of Ebola vaccines. Ther Adv Vaccines (2015) 0.92
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology (2012) 0.92
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J (2010) 0.92
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine (2011) 0.92
Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One (2015) 0.91
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tails. PLoS One (2012) 0.88
Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One (2014) 0.88
Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One (2014) 0.87
Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine (2012) 0.86
Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. J Infect Dis (2015) 0.86
Euthanasia assessment in ebola virus infected nonhuman primates. Viruses (2014) 0.85
Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum. Virol J (2011) 0.85
Unconventional secretion of Ebola virus matrix protein VP40. J Infect Dis (2011) 0.84
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
Prediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins. Virol J (2012) 0.83
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Future Virol (2015) 0.81
Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.80
An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. J Virol (2016) 0.79
Ebola virus vaccines - reality or fiction? Expert Rev Vaccines (2016) 0.79
Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. J Infect Dis (2015) 0.78
Impact of MHC class II polymorphism on blood counts of CD4+ T lymphocytes in macaque. Immunogenetics (2010) 0.78
Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling. Bioeng Bugs (2011) 0.78
An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. J Infect Dis (2016) 0.78
Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways. J Interferon Cytokine Res (2013) 0.78
Determination of specific antibody responses to the six species of ebola and marburg viruses by multiplexed protein microarrays. Clin Vaccine Immunol (2014) 0.78
Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.78
Mechanisms of immunity in post-exposure vaccination against Ebola virus infection. PLoS One (2015) 0.78
Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes. Virol J (2009) 0.78
Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. EBioMedicine (2015) 0.77
Ebola vaccines in clinical trial: The promising candidates. Hum Vaccin Immunother (2016) 0.77
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev (2016) 0.77
A thermostable, chromatographically purified Ebola nano-VLP vaccine. J Transl Med (2015) 0.77
Systems serology for evaluation of HIV vaccine trials. Immunol Rev (2017) 0.76
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS One (2016) 0.75
Technical transformation of biodefense vaccines. Vaccine (2009) 0.75
Updates on Treatment of Ebola Virus Disease. Malays J Med Sci (2015) 0.75
Cell-targeting antibodies in immunity to Ebola. Pathog Dis (2016) 0.75
Global research trends of World Health Organization's top eight emerging pathogens. Global Health (2017) 0.75
Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations. Clin Proteomics (2016) 0.75
Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses (2016) 0.75
A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. Front Immunol (2017) 0.75
Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants. Planta (2017) 0.75
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Rep (2017) 0.75
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc Natl Acad Sci U S A (2004) 2.86
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A (2005) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med (2013) 2.29
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 1.69
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis (2004) 1.44
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine (2005) 1.44
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis (2012) 1.40
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 1.27
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol (2005) 1.24
Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A (2010) 1.24
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines (2008) 1.23
Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses (2012) 1.23
Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology (2010) 1.23
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One (2012) 1.20
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine (2004) 1.19
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Antimicrob Agents Chemother (2010) 1.18
Association of ebola virus matrix protein VP40 with microtubules. J Virol (2005) 1.18
Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity. J Biol Chem (2005) 1.17
Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis (2002) 1.17
Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg Med Chem (2005) 1.16
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods (2005) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res (2002) 1.15
Identification of a small-molecule entry inhibitor for filoviruses. J Virol (2011) 1.14
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology (2004) 1.13
Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis (2007) 1.13
Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis (2011) 1.12
A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J Med Chem (2007) 1.12